close
close

OpiAID and telemedicine providers explore the use of wearables to monitor and reduce substance abuse

OpiAID and telemedicine providers explore the use of wearables to monitor and reduce substance abuse
OpiAID and telemedicine providers explore the use of wearables to monitor and reduce substance abuse

OpiAID, a Wilmington-based technology company, and Bicycle Health have announced a research pilot to determine whether wearables can help patients begin medication treatment for their opioid use disorder (MOUD) in a virtual environment.

OpiAID uses wearable technology to provide real-time monitoring, biometric insights and machine learning algorithms to support the treatment of opioid use disorder.

Bicycle Health is the leading telemedicine provider of medications for opioid use disorder (MOUD) in the United States

“With this pilot study, we are combining telemedicine for the treatment of opioid use disorder with the use of data science and wearables to use cutting-edge technology to better understand how to manage withdrawal symptoms and improve medically assisted medications for the treatment of opioid use disorder,” said David Reeser, founder and CEO of OpiAID.

Dr. Brian Clear, chief medical officer at Bicycle Health, added: “This research will investigate whether wearables and biometrics can help us better understand a patient’s response to treatment and ultimately enable us to use this data to personalize treatment and help patients achieve long-term recovery.”

The research study, which began this spring, is tracking select Bicycle Health patients who have opted in for monitoring during the first two weeks of treatment, which is often the most vulnerable and critical time in a patient’s road to recovery. Patients will wear a smartwatch that measures biometric data such as heart rate and movement. Researchers will analyze these indicators using OpiAID’s algorithms, Medsense Health’s pill bottle detectors and self-reported patient data to map out patterns.

The pilot study is scheduled to be completed in October this year.

Leave a Reply

Your email address will not be published. Required fields are marked *